Loading clinical trials...
Loading clinical trials...
Phase III Randomized Study of Four Weeks of High Dose Interferon Alfa-2b in Stage T2bN0, T3a-bN0, T4a-bN0, and T1-4, N1a,2a (Microscopic) Melanoma
Conditions
Interventions
interferon alfa-2b
observation
Locations
533
United States
UAB Comprehensive Cancer Center
Birmingham, Alabama, United States
University of South Alabama Mitchell Cancer Institute
Mobile, Alabama, United States
Arizona Cancer Center at University of Arizona Health Sciences Center
Tucson, Arizona, United States
Hembree Mercy Cancer Center at St. Edward Mercy Medical Center
Fort Smith, Arkansas, United States
Arkansas Cancer Research Center at University of Arkansas for Medical Sciences
Little Rock, Arkansas, United States
Kaiser Permanente - Deer Valley
Antioch, California, United States
Start Date
March 25, 1999
Primary Completion Date
January 1, 2015
Completion Date
December 1, 2026
Last Updated
February 25, 2026
NCT06956690
NCT05649683
NCT03543969
NCT04079166
NCT05492682
NCT05015816
Lead Sponsor
ECOG-ACRIN Cancer Research Group
Collaborators
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions